Seminars in Oncology
Volume 37, Issue 3 , Pages 216-223 , June 2010

Cancer Screening Trials: Nuts and Bolts

  • Philip C. Prorok

      Affiliations

    • Corresponding Author InformationAddress correspondence to Philip C. Prorok, PhD, Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, 6130 Executive Blvd, EPN Room 3132, Bethesda, MD 20892
    • ,
  • Pamela M. Marcus

References 

  1. Shapiro S, Venet W, Strax P, et al. Periodic screening for breast cancer—the Health Insurance Plan Project and its sequelae, 1963-1986. Baltimore, MD: Johns Hopkins University Press; 1988;
  2. Shapiro S, Venet W, Strax P, et al. Ten- to fourteen-year effect of screening on breast cancer mortality. J Natl Cancer Inst. 1982;69:349–355
  3. Tabar L, Fagerberg CJ, Gad A, et al. Reduction in mortality from breast cancer after mass screening with mammography: randomized trial from the Breast Cancer Screening Working Group of the Swedish National Board of Health and Welfare. Lancet. 1985;1:829–832
  4. Tabar L, Fagerberg G, Duffy SW, et al. Update of the Swedish two-county program of mammographic screening for breast cancer. Radiol Clin North Am. 1992;30:187–210
  5. Tabar L, Faberberg G, Day NE, et al. What is the optimum interval between mammographic screening examinations?—An analysis based on the latest results of the Swedish two-county breast cancer screening trial. Br J Cancer. 1987;55:547–551
  6. Nystrom L, Rutqvist LE, Wall S, et al. Breast cancer screening with mammography: overview of Swedish randomized trials. Lancet. 1993;341:973–978
  7. Andersson I, Aspegren K, Janzon L, et al. Mammographic screening and mortality from breast cancer: the Malmo mammographic screening trial. Br Med J. 1988;297:943–948
  8. Friskell J, Eklund G, Hellstrom L, et al. Randomized study of mammography screening – preliminary report on mortality in the Stockholm trial. Breast Cancer Res Treat. 1991;18:49–56
  9. Miller AB, Howe GR, Wall C. The national study of breast cancer screening: protocol for a Canadian randomized controlled trial of screening for breast cancer in women. Clin Invest Med. 1981;4:227–258
  10. Miller AB, Baines CJ, To T, et al. Canadian National Breast Screening Study: 1 (Breast cancer detection and death rates among women aged 40 to 49 years). Can Med Assoc J. 1992;147:1477–1488
  11. Kewenter J, Bjork S, Haglind E, et al. Screening and re-screening for colorectal cancer: a controlled trial of fecal occult blood testing in 27,700 subjects. Cancer. 1988;62:645–651
  12. Hardcastle JD, Thomas WM, Chamberlain J, et al. Randomized, controlled trial of faecal occult blood screening for colorectal cancer: results for first 107,349 subjects. Lancet. 1989;1:1160–1164
  13. Kronborg O, Fenger C, Snergaard O, et al. Initial mass screening for colorectal cancer with fecal occult blood test. Scand J Gastroenterol. 1987;22:677–686
  14. Kronborg O, Fenger C, Olsen J, et al. Repeated screening for colorectal cancer with fecal occult blood test: a prospective randomized study at Funen, Denmark. Scand J Gastroenterol. 1989;24:599–606
  15. UK Flexible Sigmoidoscopy Screening Trial Investigators. Single flexible sigmoidoscopy screening to prevent colorectal cancer: baseline findings of a UK multicentre randomized trial. Lancet. 2002;359:1291–1300
  16. Hoff G, Grotmol T, Skovlund E, Bretthauer M Norwegian Colorectal Cancer Prevention Study Group. Risk of colorectal cancer seven years after flexible sigmoidoscopy screening: randomised controlled trial. Br Med J. 2009;338:1363–1366
  17. Thiis-Evensen E, Hoff GS, Sauar J, Langmark F, Majak BM, Vatn MH. Population-based surveillance by colonoscopy: effect on the incidence of colorectal cancer. Scand J Gastroenterol. 1999;34:414–420
  18. Fontana RS, Sanderson DR, Woolner LB, et al. Screening for lung cancer: a critique of the Mayo Lung Project. Cancer. 1991;67(Suppl 1):155–164
  19. The National Lung Screening Trial Research Team. The National Lung Screening Trial: overview and study design. Radiology. In press.
  20. Van Iersel CA, de Koning HJ, Draisma G, et al. Risk-based selection for the general population in a screening trial: selection criteria, recruitment and power for the Dutch-Belgian randomized lung cancer multi-slice CT screening trial (NELSON). Int J Cancer. 2007;120:868–874
  21. Infante M, Cavuto S, Lutman FR, et al. A randomized study of lung cancer screening with spiral computed tomography: three-year results from the DANTE trial. Am J Respir Crit Care Med. 2009;180:445–453
  22. Pedersen JH, AShraf H, Dirksen A, et al. The Danish randomized lung cancer CT screening trial – overall design and results of the prevalence round. J Thorac Oncol. 2009;4:608–614
  23. Lopes Pegna A, Picozzi G, Mascalchi M, et al. Design, recruitment and baseline results of the ITALUNG trial for lung cancer screening with low-dose CT. Lung Cancer. 2009;64:34–40
  24. Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009;360:1320–1328
  25. Mandel JS, Bond JH, Church TR, et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. N Engl J Med. 1993;328:1365–1371
  26. Roberts MM, Alexander FE, Anderson TJ, et al. Edinburgh trial of screening for breast cancer: mortality at seven years. Lancet. 1990;335:241–246
  27. Miller AB, Baines CJ, To T, et al. Canadian National Breast Screening Study: 2 (Breast cancer detection and death rates among women aged 50 to 59 years). Can Med Assoc J. 1992;147:1477–1488
  28. Doria-Rose VP, Marcus PM, Szabo E, Tockman MS, Melamed MR, Prorok PC. Randomized controlled trials of the efficacy of lung cancer screening by sputum cytology revisited: a combined mortality analysis from the Johns Hopkins Lung Project and the Memorial Sloan-Kettering Lung Study. Cancer. 2009;115:5007–5017
  29. Berry DP, Clarke P, Hardcastle JD, Vellacott KD. Randomized trial of the addition of flexible sigmoidoscopy to faecal occult blood testing for colorectal neoplasia population screening. Br J Surg. 1997;84:1274–1276
  30. Rasmussen M, Kronborg O, Fenger C, Jorgensen OD. Possible advantages and drawbacks of adding flexible sigmoidoscopy to hemoccult-II in screening for colorectal cancer (A randomized study). Scand J Gastroenterol. 1999;34:73–78
  31. Verne JE, Aubrey R, Love SB, Talbot IC, Northover JM. Population based randomized study of uptake and yield of screening by flexible sigmoidoscopy compared with screening by faecal occult blood testing. BMJ. 1998;34:182–185
  32. Gohagan JK, Prorok PC, Hayes RB, Kramer BS. The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: history, organization, and status. Control Clin Trials. 2000;21:251S–272S
  33. Prorok PC, Andriole GL, Bresalier RS, et al. Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Control Clin Trials. 2000;21:273S–309S
  34. Etzioni RD, Connor RJ, Prorok PC, Self SG. Design and analysis of cancer screening tirals. Stat Methods Med Res. 1995;4:3–17
  35. Jorgensen KJ, Gotzsche PC. Overdiagnosis in publicly organized mammography screening programmes: systematic review of incidence trials. BMJ. 2009;339:206–209
  36. Esteve J, Parker L, Roy P, et al. Is neuroblastoma screening evaluation needed and feasible?. Br J Cancer. 1995;71:1125–1131
  37. Marcus PM, Bergstralh EJ, Fagerstrom RM, et al. Lung cancer mortality in the Mayo Lung Project: impact of extended follow-up. J Natl Cancer Inst. 2000;92:1308–1316
  38. Melnikow J, Nuovo J, Willan AR, Chan BKS, Howell LP. Natural history of cervical squamous intraepithelial lesions: a meta-analysis. Obstet Gynecol. 1998;92:727–735
  39. Welch HG, Albertsen PC. Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005. J Natl Cancer Inst. 2009;101:1325–1329
  40. Miller AB. Conundrums in screening for cancer. Int J Cancer. 2009;126:1039–1046
  41. Tabar L, Fagerberg G, Duffy SW, et al. Update of the Swedish two-county program of mammographic screening for breast cancer. Radiologic Clin North Am. 1992;30:187–210
  42. De Koning HJ, Liem MK, Baan CA, et al. Prostate cancer mortality reduction by screening: power and time frame with complete enrollment in the European Randomised Screening for Prostate Cancer (ERSPC) Trial. Int J Cancer. 2002;98:268–273
  43. Pinsky PF, Miller A, Kramer BS, et al. Evidence of a healthy volunteer effect in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. Am J Epidemiol. 2007;165:874–881
  44. Church TR, Ederer F, Mandel JS, Watt GD, Geisser MS. Estimating the duration of ongoing prevention trials. Am J Epidemiol. 1993;137:797–810
  45. Ederer F, Church TR, Mandel JS. Sample sizes for prevention trials have been too small. Am J Epidemiol. 1993;137:787–796
  46. Gren L, Broski K, Childs J, et al. Recruitment methods in the PLCO Cancer Screening Trial. Clin Trials. 2009;6:52–59
  47. Pinsky PF, Ford M, Gamito E, et al. Enrollment of racial and ethnic minorities in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. J Natl Med Assoc. 100;3:291-8.
  48. Hasson MA, Fagerstrom RM, Kahane DC, et al. Design and evolution of the data management systems in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Control Clin Trials. 2000;21:329S–348S
  49. Gohagan J, Marcus P, Fagerstrom R, Pinsky P, Kramer B, Prorok P. Baseline findings of a randomized feasibility trial of lung cancer screening with spiral CT scan vs. chest radiography. Chest. 2004;126:114–121
  50. Gohagan JK, Marcus PM, Fagerstrom RM, et al. Final results of the Lung Screening study, a randomized feasibility study of spiral CT versus chest X-ray screening for lung cancer. Lung Cancer. 2005;47:9–15
  51. Lawless JF. Statistical models and methods for lifetime data. New York: Wiley; 1982;
  52. Fleming TR, Harrington DP. Counting processes and survival analysis. New York: Wiley; 1991;
  53. Hakama M, Auvinen A, Day NE, Miller AB. Sensitivity in cancer screening. J Med Screen. 2007;14:174–177
  54. Croswell JM, Kramer BS, Kreimer AR, et al. Cumulative incidence of false-positive results in repeated, multimodal cancer screening. Ann Fam Med. 2009;7:212–222
  55. Mandel JS, Bond JH, Church TR, et al. Reducing mortality from colorectal cancer by screening for fecal occult blood (Minnesota Colon Cancer Control Study). N Engl J Med. 1993;328:1365–1371
  56. Smith PH. The Data Monitoring Committee—bridging the gap between urology and public health epidemiology. Br J Urol. 2003;92(Suppl 2):55–56
  57. O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics. 1979;35:549–556
  58. Lan KKG, DeMets DL. Group sequential procedures: calendar versus information time. Stat Med. 1989;8:1191–1198
  59. Lin DY, Yao Q, Ying Z. A general theory on stochastic curtailment for censored survival data. J Am Stat Assoc. 1999;94:510–521
  60. The Women's Health Initiative Study Group. Design of the Women's Health Initiative Clinical Trial and Observational Study. Control Clin Trials. 1998;19:51–109
  61. Baker SG, Kramer BS, Prorok PC. Early reporting for cancer screening trials. J Med Screen. 2008;15:122–129
  62. Baker SG, Kramer BS, Prorok PC. Statistical issues in randomized trials of cancer screening. BMC Med Res Method. 2002;2:11

PII: S0093-7754(10)00074-6

doi: 10.1053/j.seminoncol.2010.05.009

Seminars in Oncology
Volume 37, Issue 3 , Pages 216-223 , June 2010

Article Tools